|
시장보고서
상품코드
1786975
세계의 파킨슨병용 혈액 기반 바이오마커 시장 규모, 점유율, 산업 분석 리포트 : 바이오마커 유형별, 용도별, 기술 플랫폼별, 최종사용자별, 지역별 - 시장 예측(2025-2034년) |
||||||
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
Polaris Market Research의 최신 조사에 따르면 세계의 파킨슨병용 혈액 기반 바이오마커 시장 규모는 2034년까지 27억 1,191만 달러에 달할 전망입니다. 이 조사 리포트는 현재 시장 역학에 대한 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.
파킨슨병의 혈액 기반 바이오마커는 혈액에서 검출 가능한 분자 지표로 질환의 존재, 진행 및 치료 반응에 대한 인사이트를 제공합니다. 이러한 바이오마커는 증상 치료에서 적시 개입과 예방으로 전환하기 위해 의료 시스템이 조기 발견에 중점을 두면서 주목을 받고 있습니다. 저침습적 진단 접근법에 대한 수요가 증가함에 따라 임상 연구자와 진단 개발자들은 파킨슨병을 조기에 발견할 수 있는 혈액 기반 분석법을 개발하기 위해 노력하고 있습니다. 이러한 추세는 파킨슨병과 유사한 신경퇴행성 질환과의 감별에 있으며, 바이오마커의 유용성에 대한 임상의들의 인식이 높아진 데 따른 것입니다.
파킨슨병용 혈액 기반 바이오마커 시장은 바이오마커의 발견과 검증을 강화하기 위한 멀티오믹스 기술의 통합으로 형성되고 있습니다. 유전체학, 단백질체학, 대사체학의 발전으로 파킨슨병을 분자 수준에서 보다 종합적으로 이해할 수 있게 되었으며, 특이성과 민감도가 향상된 새로운 혈액 기반 바이오마커의 발굴로 이어지고 있습니다. 이러한 기술과 임상연구의 융합으로 바이오마커 개발 속도가 빨라지고 있으며, 임상시험 및 맞춤형 의료에 대한 적용도 확대되고 있습니다. 그 결과, 시장은 정밀 주도형 데이터 활용형 진단 솔루션으로 빠르게 진화하고 있습니다.
파킨슨병용 혈액 기반 바이오마커 시장 보고서의 주요 특징
용도별로는 진단용 바이오마커 부문이 2024년 2억410만 달러로 매출을 주도했습니다.
바이오마커 유형별로 살펴보면, NfL 바이오마커 부문은 여러 신경질환에서 민감한 신경퇴행성 질환의 지표로 유용성이 입증되어 예측기간 중 가장 높은 CAGR 19.00%를 보일 것으로 예측됩니다.
북미는 2024년 45.00%의 세계 점유율을 차지했는데, 이는 첨단화된 헬스케어 시스템과 주요 바이오마커 개발자 및 연구기관이 집중되어 있기 때문입니다.
아시아태평양 시장은 생물의학 연구 투자, 진단 서비스 강화, 질병에 대한 의식의 향상 캠페인 증가 등을 배경으로 2025-2034년 연평균 20.50%의 성장률을 보일 것으로 예측됩니다.
파킨슨병용 혈액 기반 바이오마커 시장에서 세계의 주요 기업에는 Abbott Laboratories, Adx Neurosciences, Alamar Biosciences, betaSENSE, F. Hoffmann-La Roche Ltd, Merck KGaA, Proteome Sciences, QIAGEN N.V., Quanterix Corporation, Thermo Fisher Scientific Inc. 등이 있습니다.
목차
제1장 서론
제2장 개요
제3장 조사 방법
제4장 세계의 파킨슨병용 혈액 기반 바이오마커 시장 분석
- 시장 스냅숏
- 파킨슨병용 혈액 기반 바이오마커 시장 역학
- 촉진요인과 기회
- 파킨슨병의 유병률 상승
- 바이오마커 발견과 검증의 진보
- 억제요인과 과제
- 표준화와 임상 검증의 결여
- 촉진요인과 기회
- PESTEL 분석
- 파킨슨병용 혈액 기반 바이오마커 시장 동향
- 밸류체인 분석
제5장 세계의 파킨슨병용 혈액 기반 바이오마커 시장 : 바이오 제조업체 유형별
- 주요 조사 결과
- 서론
- α-Syn(Alpha-Synuclein)
- NfL(Neurofilament Light Chain)
- 염증 마커
- 대사 바이오마커
- 기타
제6장 세계의 파킨슨병용 혈액 기반 바이오마커 시장 : 용도별
- 주요 조사 결과
- 서론
- 진단 바이오마커
- 예후 바이오마커
- 바이오마커 모니터링
- 치료 반응 바이오마커
- 기타
제7장 세계의 파킨슨병용 혈액 기반 바이오마커 시장 : 기술 플랫폼별
- 주요 조사 결과
- 서론
- aSyn-SAA(Alpha-Synuclein Seeding Amplification Assay)
- ELISA 기반 어세이
- 면역측정
- 질량분석
- 기타
제8장 세계의 파킨슨병용 혈액 기반 바이오마커 시장 : 최종사용자별
- 주요 조사 결과
- 서론
- 병원과 진료소
- 진단 검사실
- 연구기관
- 제약회사
제9장 세계의 파킨슨병용 혈액 기반 바이오마커 시장 : 지역별
- 주요 조사 결과
- 서론
- 파킨슨병용 혈액 기반 바이오마커 시장 평가 : 지역별, 2020-2034년
- 북미
- 북미 : 바이오 제조업체 유형별, 2020-2034년
- 북미 : 용도별, 2020-2034년
- 북미 : 기술 플랫폼별, 2020-2034년
- 북미 : 최종사용자별, 2020-2034년
- 미국
- 캐나다
- 유럽
- 유럽 : 바이오 제조업체 유형별, 2020-2034년
- 유럽 : 용도별, 2020-2034년
- 유럽 : 기술 플랫폼별, 2020-2034년
- 유럽 : 최종사용자별, 2020-2034년
- 영국
- 프랑스
- 독일
- 이탈리아
- 스페인
- 네덜란드
- 러시아
- 기타 유럽
- 아시아태평양
- 아시아태평양 : 바이오 제조업체 유형별, 2020-2034년
- 아시아태평양 : 용도별, 2020-2034년
- 아시아태평양 : 기술 플랫폼별, 2020-2034년
- 아시아태평양 : 최종사용자별, 2020-2034년
- 중국
- 인도
- 말레이시아
- 일본
- 인도네시아
- 한국
- 호주
- 기타 아시아태평양
- 중동 및 아프리카
- 중동 및 아프리카 : 바이오 제조업체 유형별, 2020-2034년
- 중동 및 아프리카 : 용도별, 2020-2034년
- 중동 및 아프리카 : 기술 플랫폼별, 2020-2034년
- 중동 및 아프리카 : 최종사용자별, 2020-2034년
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동·아아프리카
- 라틴아메리카
- 라틴아메리카 : 바이오 제조업체 유형별, 2020-2034년
- 라틴아메리카 : 용도별, 2020-2034년
- 라틴아메리카 : 기술 플랫폼별, 2020-2034년
- 라틴아메리카 : 최종사용자별, 2020-2034년
- 멕시코
- 브라질
- 아르헨티나
- 기타 라틴아메리카
제10장 경쟁 구도
- 사업 확대·인수 분석
- 사업 확대
- 인수
- 제휴/협업/협정/공개
제11장 기업 개요
- Abbott Laboratories
- Adx Neurosciences
- Alamar Biosciences
- betaSENSE
- F. Hoffmann-La Roche Ltd
- Merck KGaA
- Merck KGaA
- QIAGEN N.V.
- Quanterix Corporation
- Thermo Fisher Scientific Inc.
The blood-based biomarker for Parkinson's disease market size is expected to reach USD 2,711.91 million by 2034, according to a new study by Polaris Market Research. The report "Blood-Based Biomarker for Parkinson's Disease Market Share, Size, Trends, Industry Analysis Report By Biomarker Type [Alpha-Synuclein (a-syn), Neurofilament Light Chain (Nfl)], By Application, By Technology Platform, By End User, By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.
Blood-based biomarkers for Parkinson's disease are molecular indicators detectable in blood that provide insights into the presence, progression, and therapeutic response of the disease. These biomarkers are gaining prominence as healthcare systems focus on early-stage detection, aiming to shift from symptomatic treatment to timely intervention and prevention. The growing demand for minimally invasive diagnostic approaches is encouraging clinical researchers and diagnostic developers to advance blood-based assays capable of identifying Parkinson's at its earliest stages. This trend is also being supported by rising awareness among clinicians regarding the utility of biomarkers in differentiating Parkinson's from similar neurodegenerative disorders.
The blood-based biomarker for Parkinson's disease market is shaped by the integration of multi-omics technologies to enhance biomarker discovery and validation. Advances in genomics, proteomics, and metabolomics are enabling a more comprehensive understanding of Parkinson's disease at the molecular level, leading to the identification of novel blood-based biomarkers with improved specificity and sensitivity. This convergence of technology and clinical research is accelerating the pace of biomarker development and also expanding their applicability in clinical trials and personalized medicine. As a result, the market is evolving rapidly toward precision-driven, data-enabled diagnostic solutions.
Blood-Based Biomarker for Parkinson's Disease Market Report Highlights
In terms of application, the diagnostic biomarkers segment led revenue generation with USD 204.10 million in 2024, due to their critical role in detecting Parkinson's during early/prodromal stages when intervention is most impactful.
Based on biomarker type, the NfL biomarker segment is projected to register the highest CAGR of 19.00% during the forecast period, owing to its established utility as a sensitive neurodegeneration indicator across multiple neurological disorders.
North America held a 45.00% global share in 2024, benefiting from its advanced healthcare systems and the concentrated presence of leading biomarker developers and research institutions.
The market in Asia Pacific is expected to register a CAGR of 20.50% from 2025 to 2034, driven by investments in biomedical research, enhancements in diagnostic services, and rising awareness campaigns for diseases.
A few global key players in the blood-based biomarker for Parkinson's disease market include Abbott Laboratories, Adx Neurosciences, Alamar Biosciences, betaSENSE, F. Hoffmann-La Roche Ltd, Merck KGaA, Proteome Sciences, QIAGEN N.V., Quanterix Corporation, and Thermo Fisher Scientific Inc.
Polaris Market Research has segmented the blood-based biomarker for Parkinson's disease market report on the basis of biomarker type, application, technology platform, end user, and region:
By Biomarker Type Outlook (Revenue, USD Million, 2020-2034)
Alpha-Synuclein (a-Syn)
Neurofilament Light Chain (NfL)
Inflammatory Markers
Metabolic Biomarkers
Others
By Application Outlook (Revenue, USD Million, 2020-2034)
Diagnostic Biomarkers
Prognostic Biomarkers
Monitoring Biomarkers
Therapeutic Response Biomarkers
Others
By Technology Platform Outlook (Revenue, USD Million, 2020-2034)
Alpha-Synuclein Seeding Amplification Assay (aSyn-SAA)
ELISA-Based Assays
Immunoassays
Mass Spectrometry
Others
By End User Outlook (Revenue, USD Million, 2020-2034)
Hospitals and Clinics
Diagnostic Laboratories
Research Institutes
Pharmaceutical Companies
By Regional Outlook (Revenue, USD Million, 2020-2034)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Vietnam
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Blood-Based Biomarker for Parkinson's Disease Market Insights
- 4.1. Blood-Based Biomarker for Parkinson's Disease Market - Market Snapshot
- 4.2. Blood-Based Biomarker for Parkinson's Disease Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rising Prevalence of Parkinson's Disease
- 4.2.1.2. Advancements in Biomarker Discovery and Validation
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Lack of Standardization and Clinical Validation
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. Blood-Based Biomarker for Parkinson's Disease Market Trends
- 4.6. Value Chain Analysis
5. Global Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 5.3. Alpha-Synuclein (a-Syn)
- 5.3.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Alpha-Synuclein (a-Syn), by Region, 2020-2034 (USD Billion)
- 5.4. Neurofilament Light Chain (NfL)
- 5.4.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Neurofilament Light Chain (NfL), by Region, 2020-2034 (USD Billion)
- 5.5. Inflammatory Markers
- 5.5.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Inflammatory Markers, by Region, 2020-2034 (USD Billion)
- 5.6. Metabolic Biomarkers
- 5.6.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Metabolic Biomarkers, by Region, 2020-2034 (USD Billion)
- 5.7. Others
- 5.7.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Others, by Region, 2020-2034 (USD Billion)
6. Global Blood-Based Biomarker for Parkinson's Disease Market, by Application
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 6.3. Diagnostic Biomarkers
- 6.3.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Diagnostic Biomarkers, by Region, 2020-2034 (USD Billion)
- 6.4. Prognostic Biomarkers
- 6.4.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Prognostic Biomarkers, by Region, 2020-2034 (USD Billion)
- 6.5. Monitoring Biomarkers
- 6.5.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Monitoring Biomarkers, by Region, 2020-2034 (USD Billion)
- 6.6. Therapeutic Response Biomarkers
- 6.6.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Therapeutic Response Biomarkers, by Region, 2020-2034 (USD Billion)
- 6.7. Others
- 6.7.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Others, by Region, 2020-2034 (USD Billion)
7. Global Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 7.3. Alpha-Synuclein Seeding Amplification Assay (aSyn-SAA)
- 7.3.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Alpha-Synuclein Seeding Amplification Assay (aSyn-SAA), by Region, 2020-2034 (USD Billion)
- 7.4. ELISA-Based Assays
- 7.4.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by ELISA-Based Assays, by Region, 2020-2034 (USD Billion)
- 7.5. Immunoassays
- 7.5.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Immunoassays, by Region, 2020-2034 (USD Billion)
- 7.6. Mass Spectrometry
- 7.6.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Mass Spectrometry, by Region, 2020-2034 (USD Billion)
- 7.7. Others
- 7.7.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Others, by Region, 2020-2034 (USD Billion)
8. Global Blood-Based Biomarker for Parkinson's Disease Market, by End User
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 8.3. Hospitals and Clinics
- 8.3.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Hospitals and Clinics, by Region, 2020-2034 (USD Billion)
- 8.4. Diagnostic Laboratories
- 8.4.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Diagnostic Laboratories, by Region, 2020-2034 (USD Billion)
- 8.5. Research Institutes
- 8.5.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Research Institutes, by Region, 2020-2034 (USD Billion)
- 8.6. Pharmaceutical Companies
- 8.6.1. Global Blood-Based Biomarker for Parkinson's Disease Market, by Pharmaceutical Companies, by Region, 2020-2034 (USD Billion)
9. Global Blood-Based Biomarker for Parkinson's Disease Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Blood-Based Biomarker for Parkinson's Disease Market Assessment, By Geography, 2020-2034 (USD Billion)
- 9.3. Blood-Based Biomarker for Parkinson's Disease Market - North America
- 9.3.1. North America: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.3.2. North America: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.3.3. North America: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.3.4. North America: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.3.5. Blood-Based Biomarker for Parkinson's Disease Market - US
- 9.3.5.1. US: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.3.5.2. US: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.3.5.3. US: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.3.5.4. US: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.3.6. Blood-Based Biomarker for Parkinson's Disease Market - Canada
- 9.3.6.1. Canada: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.3.6.2. Canada: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.3.6.3. Canada: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.3.6.4. Canada: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.4. Blood-Based Biomarker for Parkinson's Disease Market - Europe
- 9.4.1. Europe: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.4.2. Europe: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.4.3. Europe: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.4.4. Europe: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.4.5. Blood-Based Biomarker for Parkinson's Disease Market - UK
- 9.4.5.1. UK: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.4.5.2. UK: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.4.5.3. UK: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.4.5.4. UK: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.4.6. Blood-Based Biomarker for Parkinson's Disease Market - France
- 9.4.6.1. France: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.4.6.2. France: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.4.6.3. France: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.4.6.4. France: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.4.7. Blood-Based Biomarker for Parkinson's Disease Market - Germany
- 9.4.7.1. Germany: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.4.7.2. Germany: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.4.7.3. Germany: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.4.7.4. Germany: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.4.8. Blood-Based Biomarker for Parkinson's Disease Market - Italy
- 9.4.8.1. Italy: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.4.8.2. Italy: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.4.8.3. Italy: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.4.8.4. Italy: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.4.9. Blood-Based Biomarker for Parkinson's Disease Market - Spain
- 9.4.9.1. Spain: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.4.9.2. Spain: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.4.9.3. Spain: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.4.9.4. Spain: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.4.10. Blood-Based Biomarker for Parkinson's Disease Market - Netherlands
- 9.4.10.1. Netherlands: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.4.10.2. Netherlands: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.4.10.3. Netherlands: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.4.10.4. Netherlands: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.4.11. Blood-Based Biomarker for Parkinson's Disease Market - Russia
- 9.4.11.1. Russia: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.4.11.2. Russia: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.4.11.3. Russia: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.4.11.4. Russia: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.4.12. Blood-Based Biomarker for Parkinson's Disease Market - Rest of Europe
- 9.4.12.1. Rest of Europe: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.4.12.2. Rest of Europe: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.4.12.3. Rest of Europe: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.4.12.4. Rest of Europe: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.5. Blood-Based Biomarker for Parkinson's Disease Market - Asia Pacific
- 9.5.1. Asia Pacific: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.5.2. Asia Pacific: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.5.3. Asia Pacific: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.5.4. Asia Pacific: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.5.5. Blood-Based Biomarker for Parkinson's Disease Market - China
- 9.5.5.1. China: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.5.5.2. China: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.5.5.3. China: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.5.5.4. China: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.5.6. Blood-Based Biomarker for Parkinson's Disease Market - India
- 9.5.6.1. India: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.5.6.2. India: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.5.6.3. India: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.5.6.4. India: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.5.7. Blood-Based Biomarker for Parkinson's Disease Market - Malaysia
- 9.5.7.1. Malaysia: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.5.7.2. Malaysia: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.5.7.3. Malaysia: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.5.7.4. Malaysia: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.5.8. Blood-Based Biomarker for Parkinson's Disease Market - Japan
- 9.5.8.1. Japan: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.5.8.2. Japan: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.5.8.3. Japan: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.5.8.4. Japan: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.5.9. Blood-Based Biomarker for Parkinson's Disease Market - Indonesia
- 9.5.9.1. Indonesia: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.5.9.2. Indonesia: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.5.9.3. Indonesia: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.5.9.4. Indonesia: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.5.10. Blood-Based Biomarker for Parkinson's Disease Market - South Korea
- 9.5.10.1. South Korea: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.5.10.2. South Korea: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.5.10.3. South Korea: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.5.10.4. South Korea: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.5.11. Blood-Based Biomarker for Parkinson's Disease Market - Australia
- 9.5.11.1. Australia: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.5.11.2. Australia: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.5.11.3. Australia: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.5.11.4. Australia: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.5.12. Blood-Based Biomarker for Parkinson's Disease Market - Rest of Asia Pacific
- 9.5.12.1. Rest of Asia Pacific: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.5.12.2. Rest of Asia Pacific: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.5.12.3. Rest of Asia Pacific: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.5.12.4. Rest of Asia Pacific: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.6. Blood-Based Biomarker for Parkinson's Disease Market - Middle East & Africa
- 9.6.1. Middle East & Africa: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.6.2. Middle East & Africa: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.6.3. Middle East & Africa: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.6.4. Middle East & Africa: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.6.5. Blood-Based Biomarker for Parkinson's Disease Market - Saudi Arabia
- 9.6.5.1. Saudi Arabia: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.6.5.2. Saudi Arabia: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.6.5.3. Saudi Arabia: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.6.5.4. Saudi Arabia: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.6.6. Blood-Based Biomarker for Parkinson's Disease Market - UAE
- 9.6.6.1. UAE: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.6.6.2. UAE: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.6.6.3. UAE: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.6.6.4. UAE: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.6.7. Blood-Based Biomarker for Parkinson's Disease Market - Israel
- 9.6.7.1. Israel: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.6.7.2. Israel: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.6.7.3. Israel: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.6.7.4. Israel: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.6.8. Blood-Based Biomarker for Parkinson's Disease Market - South Africa
- 9.6.8.1. South Africa: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.6.8.2. South Africa: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.6.8.3. South Africa: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.6.8.4. South Africa: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.6.9. Blood-Based Biomarker for Parkinson's Disease Market - Rest of Middle East & Africa
- 9.6.9.1. Rest of Middle East & Africa: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.6.9.2. Rest of Middle East & Africa: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.6.9.3. Rest of Middle East & Africa: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.6.9.4. Rest of Middle East & Africa: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.7. Blood-Based Biomarker for Parkinson's Disease Market - Latin America
- 9.7.1. Latin America: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.7.2. Latin America: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.7.3. Latin America: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.7.4. Latin America: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.7.5. Blood-Based Biomarker for Parkinson's Disease Market - Mexico
- 9.7.5.1. Mexico: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.7.5.2. Mexico: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.7.5.3. Mexico: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.7.5.4. Mexico: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.7.6. Blood-Based Biomarker for Parkinson's Disease Market - Brazil
- 9.7.6.1. Brazil: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.7.6.2. Brazil: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.7.6.3. Brazil: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.7.6.4. Brazil: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.7.7. Blood-Based Biomarker for Parkinson's Disease Market - Argentina
- 9.7.7.1. Argentina: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.7.7.2. Argentina: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.7.7.3. Argentina: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.7.7.4. Argentina: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
- 9.7.8. Blood-Based Biomarker for Parkinson's Disease Market - Rest of Latin America
- 9.7.8.1. Rest of Latin America: Blood-Based Biomarker for Parkinson's Disease Market, by Biomaker Type, 2020-2034 (USD Billion)
- 9.7.8.2. Rest of Latin America: Blood-Based Biomarker for Parkinson's Disease Market, by Application, 2020-2034 (USD Billion)
- 9.7.8.3. Rest of Latin America: Blood-Based Biomarker for Parkinson's Disease Market, by Technology Platform, 2020-2034 (USD Billion)
- 9.7.8.4. Rest of Latin America: Blood-Based Biomarker for Parkinson's Disease Market, by End User, 2020-2034 (USD Billion)
10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
- 11.1. Abbott Laboratories
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Adx Neurosciences
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Alamar Biosciences
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. betaSENSE
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. F. Hoffmann-La Roche Ltd
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. Merck KGaA
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Merck KGaA
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. QIAGEN N.V.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Quanterix Corporation
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. Thermo Fisher Scientific Inc.
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
샘플 요청 목록